||With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
GTC’s 4th Diabetes Partnering and Deal-Making Conference part of the Diabetes Summit 2014 scheduled for April 23-25, 2014 in Cambridge, MA, is a partnering and business development conference that gives companies an opportunity to network with high-level executives and explore potential collaborations, learn about relevant issues and deals that will affect the industry. The conference will bring together the leading experts on diabetes from both industry and academia to discuss business strategies and opportunities under the current regulatory landscape.